

May 19, 2023

Listing Department
BSE LIMITED

P J Towers, Dalal Street, Mumbai–400 001

Listing Department

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051

Re.: Newspaper publication

Dear Sir / Madam,

Please find attached the newspaper cutting with regard to publication of extracts of audited financial results for the quarter / year ended on March 31, 2023 in Financial Express on May 19, 2023.

Please find the same in order.

Thanking you,

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED**


DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Code: 532321

Code: ZYDUSLIFE

FINANCIAL EXPRESS



Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878


Sr. No.	CALL STATE OF THE PERSON OF TH	Rupees in Million					
	Particulars The product of the product of the particulars The product of the product of the particulars of the particulars of the particulars of the particular of the parti	3 Months ended 31/03/2023	Preceding 3 Months ended 31/12/2022	THE RESERVE AND ADDRESS OF THE PARTY OF THE	Year ended 31/03/2023	Previous year ended 31/03/2022	
4	Total Income from one-William	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)	
20	Total Income from operations	50,106	42,571	38,056	1,72,374	1,51,099	
3	Net Profit for the period before exceptional items and tax	10,871	7,801	5,729	31,939	27,254	
	Net Profit for the period after exceptional items but before tax	4,858	7,801	5,729	25,897	28,381	
	Net Profit for the period from continuing operations	2,988	6,225	4,124	19,649	22,416	
	(Loss)/ Profit after tax from discontinued operations	(22)	A 新美国 医原理的	(150)	THE RESERVE OF THE PARTY OF THE	1997 State Comment	
	Net Profit for the period after tax and Non-Controlling Interest	2,966	6,229	3,974	19,603	44,873	
The second second	Total Comprehensive Income for the period after tax and Non-Controlling Interest	3,015	5,479	3,319	16,459	43,832	
	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,024	1,012	1,024	
10	Reserves excluding Revaluation Reserve (i.e. Other Equity) Earnings per share for continuing operations (not annualised for the quarter)			8	1,74,146	1,68,972	
CARS BOX	Basic (Rs.)	2.95	6.15	4.03	19.35	21.90	
11	Diluted (Rs.) Earnings per share for continuing & discontinued operations (not annualised for the quarter)	2.95	6.15	4.03	19.35	21.90	
The State of the last	Basic (Rs.)	2.93	6.15	3.88	19.30	43.83	
Note:	Diluted (Rs.)	2.93	6.15	3.88	19.30	43.83	

[1] The above is an extract of the detailed format of Quarterly/ Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Yearly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

> > Dr. Sharvil P. Patel Managing Director DIN: 00131995

Date: May 18, 2023 Place: Ahmedabad



053,

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CTN: 124230G11995PLC025878

		Rupees in Million					
sr. No.		3 Months ended 31/03/2023	Preceding 3 Months ended 31/12/2022			Previous year ended 31/03/2022	
	Total income from operations	(Unaudited)		(Unaudited)	(Audited)	(Audited)	
2	Net Profit for the period before exceptional items and tax	50,106	42,571	38,056	1,72,374	1,51,099	
3	Net Profit for the period after exceptional items and tax Net Profit for the period from coefficients but before tax	10,871	7,801	5,729	31,939	27,254	
4 (19-1)	Net Profit for the period from continuing operations	4,858	7,801	5,729	25,897	28,381	
	(LOSS)	2,988	6,225	4,124	19,649	22,416	
5	Net Profit for the period after to	(22)	4	(150)	(46)	22,457	
	Net Profit for the period after tax and Non-Controlling Interest	2,966	6,229	3,974	19,603	44,873	
	Total Comprehensive Income for the period after tax and Non-Controlling Interest Paid-up equity share capital (Face value Re. 1/-)	3,015	5,479	3,319	16,459	43,832	
3	peserves excluding Reserves	1,012	1,012	1,024	1,012	1,024	
0	Reserves excluding Revaluation Reserve (i.e. Other Equity) Earnings per share for continuing operations (not annualised for the quarter) Basic (Rs.)				1,74,146	1,68,972	
1000	Diluted (Rs.)	2.95	6.15	4.03	19.35	21.90	
	Earnings per share for continuing & discontinued operations (not annualised for the quarter) Basic (Rs.)	2.95	6.15	4.03	19.35	21.90	
-	Diluted (Rs.)	2.93	6,15	3.88	- 19.30	43.83	
ote:		2.93	6.15	3,88	19.30	43.83	

[1] The above is an extract of the detailed format of Quarterly/ Yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Yearly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

Date: May 18, 2023 Place: Ahmedabad

WASHING TO HIS

Dr. Sharvil P. Patel Managing Director DIN: 00131995